Realtox Labs, LLC

Realtox Labs, LLC was paid $9.24M by Medicaid between Jan 2018 and Dec 2024, across 75 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 24% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Maryland

Rank by total paid#8 of 93

Median peer was paid$430K

This provider vs. median22×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	51,516	$2.61M
2019	33,106	$903K
2020	25,302	$539K
2021	48,003	$1.42M
2022	59,178	$2.06M
2023	30,587	$940K
2024incomplete	22,533	$769K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	24%	45,175	14,237	$2.20M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	23%	44,207	25,455	$2.11M
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	15%	17,669	14,178	$1.36M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	7.1%	12,892	7,013	$655K
87481		5.6%	13,469	11,160	$521K
87799		4.9%	7,572	6,069	$451K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	2.9%	3,418	2,758	$266K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	2.4%	9,680	8,374	$219K
87632		2.0%	5,623	4,503	$188K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	1.8%	4,012	3,360	$168K
87640		1.3%	14,966	12,348	$125K
87653		1.3%	14,940	12,321	$121K

63 more codes

87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	7,990	$92K
87652		<1%	7,251	$66K
81514		<1%	1,163	$63K
87482		<1%	6,899	$62K
87497		<1%	5,699	$52K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	11,308	$52K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	702	$47K
87186		<1%	5,344	$43K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	991	$39K
87900		<1%	1,503	$38K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	2,535	$37K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	2,510	$36K
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	<1%	4,015	$36K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	268	$27K
87529		<1%	1,949	$27K
87563		<1%	2,247	$23K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	890	$23K
87530		<1%	1,105	$22K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	1,503	$19K
87492		<1%	1,104	$14K
87592		<1%	1,105	$11K
87500		<1%	1,519	$11K
87641		<1%	1,404	$9K
87086	Culture, bacterial; quantitative colony count, urine	<1%	1,054	$3K
87581		<1%	278	$2K
87486		<1%	277	$2K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	97	$1K
87496		<1%	181	$716.50
80325		<1%	182	$675.91
80356		<1%	181	$485.68
80359		<1%	183	$402.59
80353		<1%	181	$330.80
83992		<1%	206	$250.57
80363		<1%	173	$240.00
80361		<1%	173	$240.00
80346		<1%	130	$217.36
80365		<1%	173	$190.44
80373		<1%	170	$177.93
80354		<1%	170	$177.93
80348		<1%	171	$177.93
80355		<1%	129	$175.12
80345		<1%	130	$145.64
80333		<1%	130	$137.61
80371		<1%	129	$137.61
80370		<1%	129	$137.61
80366		<1%	129	$137.61
80360		<1%	102	$112.59
80368		<1%	100	$100.08
80335		<1%	101	$100.08
80372		<1%	100	$100.08
80338		<1%	101	$100.08
80358		<1%	173	$76.31
81227		0%	15	$0.00
81225		0%	15	$0.00
81230		0%	15	$0.00
81240		0%	15	$0.00
81231		0%	15	$0.00
81226		0%	15	$0.00
81401		0%	15	$0.00
81355		0%	15	$0.00
81328		0%	15	$0.00
81241		0%	15	$0.00
81291		0%	15	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialGOCHNAUER, JOSHUA (OWNER)